Editas Medicine (EDIT) Stock Forecast, Price Target & Predictions
EDIT Stock Forecast
Editas Medicine stock forecast is as follows: an average price target of $17.00 (represents a 330.38% upside from EDIT’s last price of $3.95) and a rating consensus of 'Buy', based on 11 wall street analysts offering a 1-year stock forecast.
EDIT Price Target
The average price target for Editas Medicine (EDIT) is $17.00 based on 1-year price targets from 11 Wall Street analysts in the past 3 months, with a price target range of $44.00 to $7.00. This represents a potential 330.38% upside from EDIT's last price of $3.95.
EDIT Analyst Ratings
According to 11 Wall Street analysts, Editas Medicine's rating consensus is 'Buy'. The analyst rating breakdown for EDIT stock is 0 'Strong Buy' (0.00%), 7 'Buy' (63.64%), 4 'Hold' (36.36%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Editas Medicine Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 08, 2024 | Joon Lee | Truist Financial | $12.00 | $4.24 | 183.02% | 203.80% |
| Aug 08, 2024 | Greg Harrison | Bank of America Securities | $15.00 | $4.21 | 256.72% | 279.75% |
| May 30, 2024 | Liisa Bayko | Evercore ISI | $7.00 | $5.10 | 37.25% | 77.22% |
| May 09, 2024 | Matthew Harrison | Morgan Stanley | $7.00 | $5.04 | 39.03% | 77.22% |
| Sep 28, 2023 | Dae Gon Ha | Stifel Nicolaus | $17.00 | $6.92 | 145.66% | 330.38% |
| Dec 13, 2022 | - | Citigroup | $11.00 | $9.96 | 10.44% | 178.48% |
| Nov 18, 2022 | - | Morgan Stanley | $8.00 | $10.63 | -24.78% | 102.53% |
| Nov 18, 2022 | - | RBC Capital | $14.00 | $11.01 | 27.16% | 254.43% |
| Nov 18, 2022 | Joon Lee | Truist Financial | $35.00 | $11.01 | 217.89% | 786.08% |
| Nov 18, 2022 | - | Oppenheimer | $12.00 | $11.01 | 8.99% | 203.80% |
The latest Editas Medicine stock forecast, released on Aug 08, 2024 by Joon Lee from Truist Financial, set a price target of $12.00, which represents a 183.02% increase from the stock price at the time of the forecast ($4.24), and a 203.80% increase from EDIT last price ($3.95).
Editas Medicine Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 2 | 5 |
| Avg Price Target | - | $13.50 | $11.60 |
| Last Closing Price | $3.95 | $3.95 | $3.95 |
| Upside/Downside | -100.00% | 241.77% | 193.67% |
In the current month, the average price target of Editas Medicine stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Editas Medicine's last price of $3.95. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 08, 2024 | Bank of America Securities | - | Buy | Upgrade |
| Jun 18, 2024 | Oppenheimer | Buy | Buy | Hold |
| May 08, 2024 | Morgan Stanley | Underweight | Equal-Weight | Upgrade |
| May 08, 2024 | Citigroup | Buy | Buy | Hold |
| Oct 17, 2023 | Cantor Fitzgerald | Overweight | Neutral | Downgrade |
| Sep 29, 2023 | Piper Sandler | - | Buy | Upgrade |
| Jun 12, 2023 | Raymond James | - | Outperform | Upgrade |
| Feb 01, 2023 | Cantor Fitzgerald | - | Overweight | Initialise |
| Jan 04, 2023 | Wells Fargo | Overweight | Overweight | Hold |
| Dec 13, 2022 | Citigroup | - | Neutral | Initialise |
Editas Medicine's last stock rating was published by Bank of America Securities on Aug 08, 2024. The company Upgrade its EDIT rating from "null" to "Buy".
Editas Medicine Financial Forecast
Editas Medicine Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $9.85M | $6.54M | $42.00K | - | $6.77M | $12.47M | $6.20M | $379.00K | $6.50M | $11.42M | $62.84M | $10.75M | $5.72M | $12.28M | $3.85M |
| Avg Forecast | $920.21K | $867.98K | $818.72K | $772.25K | $9.34M | $3.90M | $3.90M | $3.90M | $17.82M | $4.51M | $4.78M | $11.14M | $3.70M | $3.70M | $4.17M | $3.29M | $3.66M | $4.39M | $4.29M | $3.85M | $4.64M | $4.74M | $6.03M | $5.83M | $5.64M | $6.36M | $6.34M | $6.72M | $44.61M | $4.76M |
| High Forecast | $920.21K | $867.98K | $818.72K | $772.25K | $9.34M | $3.90M | $3.90M | $3.90M | $17.82M | $15.74M | $4.78M | $11.14M | $15.40M | $3.70M | $4.17M | $3.29M | $3.66M | $4.39M | $4.29M | $8.69M | $10.47M | $10.68M | $13.59M | $13.13M | $12.72M | $14.33M | $14.28M | $15.16M | $100.58M | $10.74M |
| Low Forecast | $920.21K | $867.98K | $818.72K | $772.25K | $9.34M | $3.90M | $3.90M | $3.90M | $17.82M | $291.83K | $4.78M | $11.14M | $826.63K | $3.70M | $4.17M | $3.29M | $3.66M | $4.39M | $4.29M | $1.48M | $1.78M | $1.82M | $2.31M | $2.23M | $2.16M | $2.44M | $2.43M | $2.58M | $17.11M | $1.83M |
| # Analysts | 9 | 9 | 9 | 9 | 8 | 8 | 8 | 8 | 9 | 10 | 9 | 4 | 9 | 4 | 6 | 4 | 3 | 7 | 5 | 5 | 6 | 12 | 11 | 5 | 5 | 5 | 5 | 5 | 4 | 4 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.00% | 1.79% | 0.01% | - | 1.76% | 2.69% | 1.31% | 0.06% | 1.12% | 2.02% | 9.89% | 1.70% | 0.85% | 0.28% | 0.81% |
Editas Medicine's average Quarter revenue forecast for Jun 23 based on 6 analysts is $4.17M, with a low forecast of $4.17M, and a high forecast of $4.17M. EDIT's average Quarter revenue forecast represents a -57.65% decrease compared to the company's last Quarter revenue of $9.85M (Mar 23).
Editas Medicine EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 9 | 9 | 9 | 9 | 8 | 8 | 8 | 8 | 9 | 10 | 9 | 4 | 9 | 4 | 6 | 4 | 3 | 7 | 5 | 5 | 6 | 12 | 11 | 5 | 5 | 5 | 5 | 5 | 4 | 4 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | $-45.02M | $-40.29M | $-50.96M | $-63.45M | $-55.92M | - | $-49.19M | $-39.92M | $-37.89M | $-54.07M | $-55.56M | $-61.32M | $8.93M | $-23.29M | $-38.48M | $-38.63M | $-33.89M |
| Avg Forecast | $-920.21K | $-867.98K | $-818.72K | $-772.25K | $-9.34M | $-3.90M | $-3.90M | $-3.90M | $-17.82M | $-4.51M | $-4.78M | $-62.38M | $-3.70M | $-3.70M | $-4.17M | $-56.71M | $-3.66M | $-54.39M | $-4.29M | $-51.56M | $-46.02M | $-49.44M | $-56.61M | $-45.67M | $-39.77M | $-6.36M | $-30.80M | $-43.36M | $-187.76M | $-36.72M |
| High Forecast | $-920.21K | $-867.98K | $-818.72K | $-772.25K | $-9.34M | $-3.90M | $-3.90M | $-3.90M | $-17.82M | $-291.83K | $-4.78M | $-49.91M | $-826.63K | $-3.70M | $-4.17M | $-45.37M | $-3.66M | $-43.51M | $-4.29M | $-41.25M | $-36.82M | $-39.56M | $-45.29M | $-36.54M | $-31.82M | $-2.44M | $-24.64M | $-34.69M | $-150.21M | $-29.37M |
| Low Forecast | $-920.21K | $-867.98K | $-818.72K | $-772.25K | $-9.34M | $-3.90M | $-3.90M | $-3.90M | $-17.82M | $-15.74M | $-4.78M | $-74.86M | $-15.40M | $-3.70M | $-4.17M | $-68.06M | $-3.66M | $-65.27M | $-4.29M | $-61.87M | $-55.23M | $-59.33M | $-67.93M | $-54.80M | $-47.73M | $-14.33M | $-36.96M | $-52.03M | $-225.31M | $-44.06M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 12.16% | 9.66% | 0.90% | 17.34% | 1.03% | - | 0.95% | 0.87% | 0.77% | 0.96% | 1.22% | 1.54% | -1.40% | 0.76% | 0.89% | 0.21% | 0.92% |
5 analysts predict EDIT's average Quarter EBITDA for Dec 20 to be $-39.77M, with a high of $-31.82M and a low of $-47.73M. This is -545.58% lower than Editas Medicine's previous annual EBITDA (Sep 20) of $8.93M.
Editas Medicine Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 9 | 9 | 9 | 9 | 8 | 8 | 8 | 8 | 9 | 10 | 9 | 4 | 9 | 4 | 6 | 4 | 3 | 7 | 5 | 5 | 6 | 12 | 11 | 5 | 5 | 5 | 5 | 5 | 4 | 4 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | $-45.02M | $-40.29M | $-45.57M | $-55.03M | $-53.93M | - | $-50.28M | $-41.44M | $-39.08M | $-55.26M | $-56.73M | $-62.50M | $7.82M | $-23.57M | $-37.72M | $-37.77M | $-32.94M |
| Avg Forecast | $-38.04M | $-66.00M | $-62.24M | $-62.39M | $-54.78M | $-59.63M | $-58.57M | $-58.10M | $-48.91M | $-64.02M | $-57.95M | $-64.99M | $-48.89M | $-47.34M | $-63.12M | $-59.08M | $-64.91M | $-56.10M | $-66.23M | $-53.71M | $-47.77M | $-51.00M | $-57.86M | $-46.63M | $-40.54M | $15.39M | $-31.17M | $-42.50M | $-183.56M | $-35.69M |
| High Forecast | $-38.04M | $-66.00M | $-62.24M | $-62.39M | $-54.78M | $-59.63M | $-58.57M | $-58.10M | $-48.91M | $-37.56M | $-57.95M | $-51.99M | $19.74M | $-47.34M | $-63.12M | $-47.27M | $-64.91M | $-44.88M | $-66.23M | $-42.97M | $-38.21M | $-40.80M | $-46.29M | $-37.30M | $-32.43M | $18.47M | $-24.93M | $-34.00M | $-146.85M | $-28.55M |
| Low Forecast | $-38.04M | $-66.00M | $-62.24M | $-62.39M | $-54.78M | $-59.63M | $-58.57M | $-58.10M | $-48.91M | $-75.97M | $-57.95M | $-77.99M | $-70.52M | $-47.34M | $-63.12M | $-70.90M | $-64.91M | $-67.32M | $-66.23M | $-64.45M | $-57.32M | $-61.20M | $-69.43M | $-55.95M | $-48.65M | $12.31M | $-37.40M | $-51.00M | $-220.27M | $-42.82M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.95% | 0.64% | 0.77% | 0.85% | 0.96% | - | 0.94% | 0.87% | 0.77% | 0.96% | 1.22% | 1.54% | 0.51% | 0.76% | 0.89% | 0.21% | 0.92% |
Editas Medicine's average Quarter net income forecast for Dec 20 is $-40.54M, with a range of $-48.65M to $-32.43M. EDIT's average Quarter net income forecast represents a -618.48% decrease compared to the company's last Quarter net income of $7.82M (Sep 20).
Editas Medicine SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 9 | 9 | 9 | 9 | 8 | 8 | 8 | 8 | 9 | 10 | 9 | 4 | 9 | 4 | 6 | 4 | 3 | 7 | 5 | 5 | 6 | 12 | 11 | 5 | 5 | 5 | 5 | 5 | 4 | 4 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | $14.99M | $17.20M | $23.01M | $17.98M | $16.24M | - | $19.55M | $16.53M | $16.18M | $22.03M | $21.45M | $15.79M | $19.94M | $14.08M | $17.77M | $16.92M | $15.73M |
| Avg Forecast | $2.09M | $1.97M | $1.86M | $1.75M | $21.21M | $8.86M | $8.86M | $8.86M | $40.46M | $10.24M | $10.85M | $25.29M | $8.39M | $8.41M | $9.47M | $7.46M | $8.30M | $9.97M | $9.74M | $8.75M | $10.54M | $10.76M | $13.68M | $13.22M | $12.81M | $14.43M | $14.38M | $15.27M | $101.27M | $10.82M |
| High Forecast | $2.09M | $1.97M | $1.86M | $1.75M | $21.21M | $8.86M | $8.86M | $8.86M | $40.46M | $35.72M | $10.85M | $25.29M | $34.96M | $8.41M | $9.47M | $7.46M | $8.30M | $9.97M | $9.74M | $19.72M | $23.77M | $24.25M | $30.85M | $29.81M | $28.88M | $32.54M | $32.43M | $34.42M | $228.32M | $24.39M |
| Low Forecast | $2.09M | $1.97M | $1.86M | $1.75M | $21.21M | $8.86M | $8.86M | $8.86M | $40.46M | $662.44K | $10.85M | $25.29M | $1.88M | $8.41M | $9.47M | $7.46M | $8.30M | $9.97M | $9.74M | $3.35M | $4.04M | $4.12M | $5.25M | $5.07M | $4.91M | $5.53M | $5.51M | $5.85M | $38.83M | $4.15M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.78% | 1.82% | 3.09% | 2.17% | 1.63% | - | 2.23% | 1.57% | 1.50% | 1.61% | 1.62% | 1.23% | 1.38% | 0.98% | 1.16% | 0.17% | 1.45% |
Editas Medicine's average Quarter SG&A projection for Dec 23 is $8.39M, based on 9 Wall Street analysts, with a range of $1.88M to $34.96M. The forecast indicates a -43.99% fall compared to EDIT last annual SG&A of $14.99M (Sep 23).
Editas Medicine EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 9 | 9 | 9 | 9 | 8 | 8 | 8 | 8 | 9 | 10 | 9 | 4 | 9 | 4 | 6 | 4 | 3 | 7 | 5 | 5 | 6 | 12 | 11 | 5 | 5 | 5 | 5 | 5 | 4 | 4 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | $-0.00 | $-0.00 | $-0.66 | $-0.80 | $-0.78 | - | $-0.73 | $-0.61 | $-0.57 | $-0.81 | $-0.86 | $-1.00 | $0.13 | $-0.43 | $-0.69 | $-0.74 | $-0.66 |
| Avg Forecast | $-0.46 | $-0.80 | $-0.76 | $-0.76 | $-0.67 | $-0.72 | $-0.71 | $-0.71 | $-0.59 | $-0.78 | $-0.70 | $-0.63 | $-0.59 | $-0.58 | $-0.77 | $-0.78 | $-0.79 | $-0.85 | $-0.81 | $-0.78 | $-0.71 | $-0.81 | $-0.82 | $-0.74 | $-0.76 | $-0.63 | $-0.79 | $-0.79 | $0.05 | $-0.71 |
| High Forecast | $-0.46 | $-0.80 | $-0.76 | $-0.76 | $-0.67 | $-0.72 | $-0.71 | $-0.71 | $-0.59 | $-0.46 | $-0.70 | $-0.63 | $0.24 | $-0.58 | $-0.77 | $-0.78 | $-0.79 | $-0.85 | $-0.81 | $-0.16 | $-0.14 | $-0.16 | $-0.16 | $-0.15 | $-0.15 | $-0.12 | $-0.16 | $-0.16 | $0.13 | $-0.14 |
| Low Forecast | $-0.46 | $-0.80 | $-0.76 | $-0.76 | $-0.67 | $-0.72 | $-0.71 | $-0.71 | $-0.59 | $-0.92 | $-0.70 | $-0.63 | $-0.86 | $-0.58 | $-0.77 | $-0.78 | $-0.79 | $-0.85 | $-0.81 | $-2.06 | $-1.87 | $-2.14 | $-2.17 | $-1.96 | $-2.00 | $-1.65 | $-2.07 | $-2.07 | $0.01 | $-1.86 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.00% | 0.00% | 0.84% | 1.01% | 0.91% | - | 0.93% | 0.86% | 0.70% | 0.98% | 1.16% | 1.32% | -0.21% | 0.55% | 0.88% | -14.80% | 0.93% |
According to 5 Wall Street analysts, Editas Medicine's projected average Quarter EPS for Dec 20 is $-0.76, with a low estimate of $-2.00 and a high estimate of $-0.15. This represents a -684.62% decrease compared to EDIT previous annual EPS of $0.13 (Sep 20).
Editas Medicine Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| ALLO | Allogene Therapeutics | $2.96 | $29.00 | 879.73% | Buy |
| NTLA | Intellia Therapeutics | $22.07 | $119.16 | 439.92% | Buy |
| EDIT | Editas Medicine | $3.95 | $17.00 | 330.38% | Buy |
| PRME | Prime Medicine | $4.09 | $17.25 | 321.76% | Buy |
| VERV | Verve Therapeutics | $5.50 | $21.50 | 290.91% | Buy |
| SANA | Sana Bio | $4.47 | $12.00 | 168.46% | Buy |
| BEAM | Beam Therapeutics | $26.30 | $64.20 | 144.11% | Buy |
| CRSP | CRISPR Therapeutics | $48.94 | $109.58 | 123.91% | Buy |
| CRBU | Caribou Biosciences | $2.12 | $3.00 | 41.51% | Buy |
| DNA | Ginkgo Bioworks | $6.32 | $7.34 | 16.14% | Buy |
| VRTX | Vertex Pharmaceuticals | $485.37 | $381.05 | -21.49% | Buy |
EDIT Forecast FAQ
Is Editas Medicine a good buy?
Yes, according to 11 Wall Street analysts, Editas Medicine (EDIT) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 7 'Buy' recommendations, accounting for 63.64% of EDIT's total ratings.
What is EDIT's price target?
Editas Medicine (EDIT) average price target is $17 with a range of $7 to $44, implying a 330.38% from its last price of $3.95. The data is based on 11 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Editas Medicine stock go up soon?
According to Wall Street analysts' prediction for EDIT stock, the company can go up by 330.38% (from the last price of $3.95 to the average price target of $17), up by 1013.92% based on the highest stock price target, and up by 77.22% based on the lowest stock price target.
Can Editas Medicine stock reach $6?
EDIT's average twelve months analyst stock price target of $17 supports the claim that Editas Medicine can reach $6 in the near future.
What are Editas Medicine's analysts' financial forecasts?
Editas Medicine's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $21.05M (high $21.05M, low $21.05M), average EBITDA is $-21.051M (high $-21.051M, low $-21.051M), average net income is $-231M (high $-231M, low $-231M), average SG&A $47.79M (high $47.79M, low $47.79M), and average EPS is $-2.807 (high $-2.807, low $-2.807). EDIT's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $3.38M (high $3.38M, low $3.38M), average EBITDA is $-3.379M (high $-3.379M, low $-3.379M), average net income is $-229M (high $-229M, low $-229M), average SG&A $7.67M (high $7.67M, low $7.67M), and average EPS is $-2.778 (high $-2.778, low $-2.778).
Did the EDIT's actual financial results beat the analysts' financial forecasts?
Based on Editas Medicine's last annual report (Dec 2022), the company's revenue was $19.71M, beating the average analysts forecast of $16.19M by 21.74%. Apple's EBITDA was $-226M, beating the average prediction of $-114M by 98.39%. The company's net income was $-204M, missing the average estimation of $-241M by -15.19%. Apple's SG&A was $70.7M, beating the average forecast of $36.76M by 92.36%. Lastly, the company's EPS was $-2.98, missing the average prediction of $-3.232 by -7.78%. In terms of the last quarterly report (Mar 2023), Editas Medicine's revenue was $9.85M, beating the average analysts' forecast of $3.29M by 199.87%. The company's EBITDA was $-50.961M, missing the average prediction of $-56.713M by -10.14%. Editas Medicine's net income was $-45.567M, missing the average estimation of $-59.083M by -22.88%. The company's SG&A was $23.01M, beating the average forecast of $7.46M by 208.54%. Lastly, the company's EPS was $-0.66, missing the average prediction of $-0.784 by -15.83%